Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $2.8B | $2.7B | $2.8B | $684M | $698.9M | |
| Gross Profit | $1.5B | $1.4B | $1.4B | $384.8M | $325.9M | |
| Operating Income | $450.9M | $377.6M | $415.9M | $102.6M | $90.9M | |
| EBITDA | $881.3M | $805.9M | $823.2M | $210.3M | $192.9M | |
| Diluted EPS | $5.95 | $2.46 | $2.00 | $0.76 | $0.41 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2.3B | $3.1B | $2.9B | $2.4B | $2.1B | |
| Total Assets | $14.9B | $13.8B | $13.4B | $12.8B | $12.1B | |
| Current Liabilities | $1.1B | $1.5B | $1.4B | $687.9M | $1.2B | |
| Total Liabilities | $7.9B | $6.8B | $5.7B | $4.8B | $4.8B | |
| Total Equity | $7B | $7.1B | $7.7B | $7.9B | $7.4B | |
| Total Debt | $5.3B | $4.5B | $4B | $3.3B | $3.4B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $33.8M | $650.7M | $572.7M | $147.9M | $138.5M | |
| Cash From Investing | $1.7B | $378.7M | -$14.2M | $690.2M | $19M | |
| Cash From Financing | -$1B | -$954.9M | -$871.7M | -$873.7M | -$215.1M | |
| Free Cash Flow | -$49.6M | -$657.2M | $494.9M | $125.6M | $120M | |
Revvity, Inc. provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. It focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, and informatics. The firm operates through the following segments: Life Sciences and Diagnostics. The Life Sciences segment delivers innovative solutions to optimize workflows, boost productivity, and accelerate drug discovery and development. The Diagnostics segment provides instruments, reagents, assay platforms, and software to healthcare and research professionals, with a focus on reproductive health, immunodiagnostics, emerging market diagnostics, and applied genomics to enhance patient outcomes. Revvity was founded on April 19, 1937 and is headquartered in Waltham, MA.
In the current month, RVTY has received 8 Buy ratings 8 Hold ratings, and 0 Sell ratings. The RVTY average analyst price target in the past 3 months is $114.38.
According to analysts, the consensus estimate is that Revvity, Inc. share price will rise to $114.38 per share over the next 12 months.
Analysts are divided on their view about Revvity, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Revvity, Inc. is a Sell and believe this share price will drop from its current level to $100.00.
The price target for Revvity, Inc. over the next 1-year time period is forecast to be $114.38 according to 16 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 8 analysts rate the stock a Hold.
According to Wall Street analysts, the consensus rating for Revvity, Inc. is a Leans Bullish. 8 of 16 analysts rate the stock a Leans Bullish at this time.
You can purchase shares of Revvity, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Revvity, Inc. shares.
Revvity, Inc. was last trading at $97.03 per share. This represents the most recent stock quote for Revvity, Inc.. Yesterday, Revvity, Inc. closed at $96.78 per share.
In order to purchase Revvity, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Signup to receive the latest stock alerts
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Market Cap: $4.6T
P/E Ratio: 64x
Market Cap: $4T
P/E Ratio: 37x
Market Cap: $3.8T
P/E Ratio: 39x
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.